Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Former Philadelphia Eagles quarterback Rodney Peete joined Sumitomo Pharma America’s Time to Go campaign. 1 The promotional ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Stand Up To Cancer returns on August 15. The biennial fundraising event is scheduled to occur in Nashville this year, which ...

Results from the Phase III VEGA-3 trial show that a significantly higher number of patients with presbyopia who received ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...